Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD)

September 2006

Glaxo will be promoting Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD).

It's the first drug approved for this use.

Up to 10% of people living in northern latitudes get depressed in the fall and winter. It's thought that shorter days trigger changes in melatonin, serotonin, and other neurotransmitters.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote